市場調查報告書
商品編碼
1184255
血管貼片全球市場規模、份額、行業趨勢分析報告:按材料(生物/合成)、最終用戶(醫院/門診手術中心)、應用和地區預測2022-2028Global Vascular Patches Market Size, Share & Industry Trends Analysis Report By Material (Biologic and Synthetic), By End User (Hospitals and Ambulatory Surgical Centers), By Application, By Regional Outlook and Forecast, 2022 - 2028 |
全球血管貼片市場規模預計將在 2028 年達到 5.29 億美元,預測期內復合年增長率為 7.1%。
血管外科具有許多與其他臨床領域不同的特點。 雖然大多數血管手術都是乾淨的,但頻繁使用人工移植物通常會增加感染的可能性。 此外,接受血管手術的患者通常年齡較大,並且更有可能患有許多疾病,例如糖尿病、免疫系統減弱、免疫紊亂、高血壓和心髒病。
在胰腺或腎臟移植的情況下,不僅是移植器官,而且接受者的生命和四肢都可能因感染性血管疾病而受到威脅。 這種嚴重的血管疾病可能需要復雜的血管修復或血管切除術。 血管疾病患病率上升、老年人口迅速增加、生物補片流行、血管手術數量增加等是推動全球血管補片市場的因素。
COVID-19 影響分析
除了與 COVID-19 相關的後遺症外,患者入院延遲和急診資源轉移對接受血管手術的患者的健康也有重大影響。 儘管在 COVID-19 手術室法規的應用、個人防護設備 (PPE) 的可用性或遵守國家手術標準方面沒有地區差異,但許多手術已被取消或有選擇地推遲。稻田。 由於大流行,獲得血管外科服務和患者的機會受到嚴重限制。 血管治療以與以往完全不同的方式進行。 許多門診診所和門診血管外科醫生報告了實踐中的變化,包括獲得遠程醫療服務和縮短諮詢時間。 對住院服務的影響同樣顯著。
市場增長因素
不斷增長的老年人口和不斷增加的血管疾病患病率
CVD、高血壓、高血脂、中風、癌症、動脈瘤等各種疾病發病率不斷上升的主要原因之一是全球老齡化人口的迅速膨脹。這是因為 人口老齡化被認為是心臟健康狀況下降的主要因素,因此使其成為市場增長的關鍵預測指標。 世界衛生組織預測,到 2030 年,世界上六分之一的人將超過 60 歲。
血管治療的報銷選項
血管外科醫生在手術期間在支持其他外科專家方面發揮著重要作用。 這種手術支持的頻率和經濟價值大,貢獻和邊際貢獻率也大。 作為顧問醫師,血管外科醫生還通過解決極其複雜的病例為醫院增加了顯著的經濟價值。 患者的第一個特點是患有多種疾病。 這意味著同時患有兩種或多種慢性病。
市場約束
對合格人員的需求增加。
血管補片應由熟練人員處理,因為手術後動脈閉合不充分會導致持續出血和缺血。 此外,在使用小工具時,許多操作必須按順序執行。 目前阻礙其傳播的是發達國家和新興國家外科醫生的短缺。 例如,根據美國醫學院協會 (AAMC) 的數據,到 2032 年,美國預計將缺少 122,000 名醫生。
材料展望
按材料劃分,市場分為生物材料和合成材料。 2021年血管貼片的市場份額將是生物血管貼片最大的,主要是因為其易於應用、術後感染風險低、生物相容性高。 生物血管補片的可生物降解質量和更高的拉伸強度和縫線保持強度是其兩個主要優勢。
應用展望
根據應用,市場已細分為頸動脈內膜切除術、腹動脈瘤開放修復術、血管旁路手術、先天性心髒病等。 到 2021 年,頸動脈內膜切除術將佔據市場最大的收入份額。 為了緩解頸動脈狹窄並降低中風的風險,必須在稱為頸動脈內膜切除術的手術中打開頸動脈。 當動脈在手術結束時閉合時,通過修補動脈開口可以降低中風的風險。
最終用戶展望
根據最終用戶,市場分為醫院和門診手術中心。 預計門診手術中心將在預測期內見證最快的增長。 根據門診手術中心協會的說法,門診手術中心 (ASC) 是一種全新類型的醫療機構,旨在提供當日手術治療,包括診斷和預防程序。
區域展望
按地域劃分,分為北美、歐洲、亞太、LAMEA。 由於該地區老年人口不斷增長和心血管疾病患病率高,預計北美將在全球血管貼片市場中佔據領先地位。 例如,根據美國人口普查局2015年3月的一篇文章,該國的老年人口將從2014年的3.19億增長到2060年的4億多,到2051年預計將達到4億。
The Global Vascular Patches Market size is expected to reach $529 Million by 2028, rising at a market growth of 7.1% CAGR during the forecast period.
Vascular patches are microporous polyester-urethane patches used in vascular procedures to close the wound with sutures. The World Health Organization (WHO) reports that cardiovascular diseases-which take 17.9 million lives annually-are the main cause of death. Vascular patches have great tissue integration, are highly biocompatible, have low infectious potential, low suture line bleeding, don't require impregnation or pre-clotting, and have good handling characteristics.
Due to the growing frequency of cardiac difficulties, technological advancements, and improvements in healthcare, the global market for vascular patches is anticipated to develop profitably in the years to come. A recent cross-disciplinary area of medical study is vascular surgery. Vascular surgeries are classed in that a range of artificial grafts (stents, stent-grafts, artificial blood vessels) are commonly used in clinical disciplines.
Vascular surgeries have many features with other clinical disciplines. Although most vascular surgical procedures are clean, the likelihood of infection is typically substantial since artificial grafts are frequently used. Additionally, patients undergoing vascular surgery are frequently elderly and are more likely to have a number of internal medical conditions, including diabetes, weak immune systems, immunological disorders, hypertension, and heart disease.
After pancreas or kidney transplantation, infectious vascular problems can put the recipient's life and limb, as well as the donated organ, in danger. These serious disorders can call for intricate vascular repair and vascular excision. The prevalence of vascular disorders is rising, the geriatric population is expanding quickly, biological patches are being more widely used, and there are more vascular surgeries being conducted, all of which are factors that are propelling the worldwide vascular patches market.
COVID-19 Impact Analysis
Patients delaying hospital exposure and diverting resources to urgent care have had a significant impact on the health of patients undergoing vascular surgery, in addition to COVID-19-related aftereffects. Despite no regional variation in the application of COVID-19 operating room rules, accessibility to personal protective equipment (PPE), or compliance with national surgical standards, many surgeries were either canceled or postponed electively. Vascular surgery services and patient access have been severely limited as a result of the pandemic. Vascular care is being delivered in a very different way. Many vascular surgeons who practice in outpatient clinics and ambulatory care reported that their practice has altered, including the use of telemedicine services and shorter hours. The impact on inpatient services was likewise significant.
Market Growth Factors
Increasing Geriatric Population And Rising Vascular Disease Prevalence
One of the main causes of the rising occurrence of various diseases and ailments, including CVDs, hypertension, high cholesterol, strokes, cancer, and aneurysms, is the rapidly expanding senior population worldwide. The aging population is a key predictor of market growth because it is thought that aging is a major factor in the decline of cardiac health. By 2030, one in every six people worldwide will be 60 years of age or older, predicts the WHO.
Reimbursement Options For Vascular Treatments
Vascular surgeons support other surgical specialties during operations in a crucial way. The frequency and financial worth of this operational support, which has a large contribution margin and contribution margin ratio, are substantial. Vascular surgeons, in their function as consulting surgeons, facilitate the resolution of extremely complex cases and, in doing so, add significantly to the hospital's financial value. The primary characteristic of patients is multi-morbidity. It denotes the concurrent presence of two or more chronic diseases.
Market Restraining Factors
Growing requirement for qualified personnel.
Vascular patches must be handled by skilled personnel since poor artery closure following surgery can result in ongoing bleeding or ischemia. While using some gadgets, many actions must be taken in order. One of the main barriers preventing the widespread use of these goods at the moment is the shortage of surgeons in both industrialized and emerging nations. For instance, the US is expected to experience a 122,000 physician deficit by 2032, according to the Association of American Medical Colleges (AAMC).
Material Outlook
Based on material, the market is classified into biologic and synthetic. The biologic vascular patch segment held the largest market share for vascular patches in 2021, mainly because it was easier to apply, had a lower risk of infection after surgery, and had greater biocompatibility. The biologic vascular patches' biodegradable quality and greater tensile and suture retention strength are two of their key advantages.
Application Outlook
Based on Applications, the market was categorized into Carotid Endarterectomy, Open Repair of Abdominal Aneurysm, Vascular Bypass Surgery, Congenital Heart Diseases, and Others. During 2021, carotid endarterectomy gained the largest revenue share in the market. In order to relieve this narrowing and so lower the risk of stroke, a procedure known as a carotid endarterectomy requires opening the carotid artery. The risk of strokes is decreased by placing a patch into the opening in the artery as the artery is closed at the end of the procedure.
End-user Outlook
Based on the End-user, the market is categorized into Hospitals and Ambulatory Surgical Centers. Ambulatory surgery centers are anticipated to experience the fastest growth during the forecasted timeframe. According to the ambulatory surgical center association, ambulatory surgery centers (ASCs) are a brand-new type of healthcare institution designed to provide same-day surgical treatment, including diagnostic and preventative procedures.
Regional Outlook
Based on geography, the market is classified into North America, Europe, Asia Pacific, and LAMEA. Due to the rising elderly population and the high prevalence of cardiovascular illnesses in the region, North America is predicted to have a leading position in the global market for vascular patches. For instance, a March 2015 article from the US Census Bureau states that the country's elderly population is projected to rise from 319 million in 2014 to more than 400 million in 2060, hitting 400 million in 2051.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Edwards Lifesciences Corporation, Baxter International, Inc., Lemaitre Vascular, Inc., Becton, Dickinson and Company, Terumo Corporation, Aziyo Biologics, Inc., Getinge AB, B. Braun Melsungen AG, Artivion, Inc. (CryoLife, Inc.), and W. L. Gore & Associates, Inc.
Strategies Deployed in Vascular Patches Market
Sep-2022: Edwards Lifesciences released the SAPIEN 3 Ultra RESILIA valve, a catheter-based artificial heart valve system consisting of RESILIA tissue technology. This launch shows the Company's effort in innovations to address the present and future requirements of patients to help them live healthier, longer, and more productive.
Sep-2022: W. L. Gore & Associates took over InnAVasc Medical, a small medical technology company. Through this acquisition, W. L. Gore & Associates would add InnAVasc's investigational technology to strengthen the company's plan to enhance patients' lives by delivering physicians-developed treatment solutions in dialysis access space.
Dec-2021: Becton, Dickinson, and Company completed the acquisition of Venclose, Inc., a medical technology company. Under this acquisition, Becton, Dickinson, and Company would broaden developments in the treatment of Chronic Venous Disease. Additionally, the acquisition would allow the company to offer a strong suite of solutions to physicians treating the complete extent of venous conditions.
Dec-2021: Baxter International Inc. completed the acquisition of Hillrom, a provider of medical technology. This acquisition would help Baxter in reaching another level of transformation, offering a new wave of ability to deliver better results for employees, shareholders, patients, and other parties whom the company serves globally.
Jan-2020: Terumo released New Surgical Sealant AQUABRID®, a new surgical sealant developed for aortic procedures, across the EMEA market. The product would deliver a new market for the business in a segment of growing importance for its business.
Oct-2019: LeMaitre Vascular, Inc. took over the biologic patch business of Admedus Ltd., a structural heart company engaged in offering clinically advanced solutions. The patches taken over by LeMaitre Vascular, Inc. are marketed under the brands VascuCel and CardioCel and are designed in a way to decrease the risk of calcification.
Apr-2019: Edwards Lifesciences Corporation took over CAS Medical Systems, Inc., a medical technology engaged in the monitoring of non-invasive brain and tissue oxygenation. Under This acquisition, Edwards would combine HemoSphere's advanced hemodynamic monitoring platform with FORE-SIGHT technology to build a specific suite of better recovery tools and abilities of predictive analytics for clinicians.
Oct-2018: LeMaitre Vascular Inc. acquired Cardial, a subsidiary of Becton, Dickinson & Company, a medical technology company. Under this acquisition, LeMaitre Vascular Inc. would broaden its global presence in the area of supporting vascular surgeons.
Market Segments covered in the Report:
By Material
By End User
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures